Hesperidin supplementation has no effect on blood glucose control: a systematic review and meta-analysis of randomized controlled clinical trials.
What this study found
Hesperidin supplementation did not improve blood glucose control or insulin sensitivity versus placebo/control. Pooled random-effects analyses showed no significant effect on fasting blood glucose (WMD -1.10 mg/dL, 95% CI -3.79 to 1.57; P = .844), HbA1c (WMD -0.04%, 95% CI -0.14 to 0.04; P = .321), HOMA-IR (WMD 0.117, 95% CI -0.06 to 0.29; P = .208), or QUICKI (WMD 0.135, 95% CI -0.13 to 0.39; P = .319). Heterogeneity was low for fasting blood glucose, HbA1c, and HOMA-IR (I2 = 0% for each) but extreme for QUICKI (I2 = 99.7%). The authors concluded that hesperidin does not show a confirmed…
- Study & population
- Systematic review and meta-analysis of randomized controlled clinical trials in adults older than 18 years.
- Intervention
- Hesperidin was evaluated in 6 randomized trials using oral daily dosing of 450 mg/day to 500 mg/day for 3 to 8 weeks in most studies, with two crossover beverage trials using hesperidin-containing juice or beverage formulations.
- Key limitation
- Only 6 trials were included, and several outcomes were informed by very few studies (HbA1c n = 2, HOMA-IR n = 3, QUICKI n = 2).
View source
Open PDFOriginal abstract
AIM To the best of our knowledge, no study has tried to quantitatively summarize the published evidence regarding the effect of hesperidin supplementation on blood glucose control. The present systematic review and meta-analysis of randomized controlled trials aimed to determine the effectiveness of hesperidin supplementation in improving blood glucose control in adults. MATERIALS AND METHODS Electronic databases including PubMed, ISI Web of Science, Scopus, and Google Scholar were searched up to February 2019. The risk of bias in individual studies was assessed using the Cochrane collaboration's tool. The overall estimates and their 95% confidence intervals (CIs) were calculated using a random-effects model. RESULTS Six trials with 318 participants were reviewed in the present systematic review. The results showed that hesperidin had no significant effect on serum fasting blood glucose (WMD = -1.10 mg/dL, 95% CI: -3.79, 1.57), plasma insulin (WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19), glycated hemoglobin A1c (WMD = -0.04%, 95% CI: -0.14, 0.04), homeostasis model assessment for insulin resistance (HOMA-IR) (WMD = 0.117, 95% CI: -0.06, 0.29) and quantitative insulin sensitivity check index (QUICKI) (WMD = 0.135; 95% CI: -0.13, 0.39), with no significant between-study heterogeneity. Subgroup analyses also indicated that the effects were not different based on the studies' design andduration, or the health status of the participants. CONCLUSION Although several animal studies have proposed that hesperidin supplementation might improve blood glucose control, the present study could not confirm this benefit in humans.